Which has preferable valuation and earnings, IMUX or AURA?

Aura Biosciences is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunic N/A N/A -$97.17M -$5.58 N/A Aura Biosciences N/A N/A -$106.19M -$1.74 N/A

Is IMUX or AURA more profitable?

Aura Biosciences' return on equity of -78.12% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Immunic N/A -220.75% -132.04% Aura Biosciences N/A -78.12% -64.08%

Which has better valuation and earnings, IMUX or CADL?

Candel Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunic N/A N/A -$97.17M -$5.58 N/A Candel Therapeutics N/A N/A -$38.18M -$0.98 N/A

Is IMUX or CADL more profitable?

Candel Therapeutics' return on equity of -60.42% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Immunic N/A -220.75% -132.04% Candel Therapeutics N/A -60.42% -41.33%

Does the media prefer IMUX or CADL?

In the previous week, Immunic had 3 more articles in the media than Candel Therapeutics. MarketBeat recorded 7 mentions for Immunic and 4 mentions for Candel Therapeutics. Immunic's average media sentiment score of 0.77 beat Candel Therapeutics' score of 0.19 indicating that Immunic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunic 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Candel Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, DRUG or IMUX?

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bright Minds Biosciences N/A N/A -$8.74M -$2.44 N/A Immunic N/A N/A -$97.17M -$5.58 N/A

Is DRUG or IMUX more profitable?

Bright Minds Biosciences' return on equity of -20.58% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Bright Minds Biosciences N/A -20.58% -20.25% Immunic N/A -220.75% -132.04%

Does the media favor DRUG or IMUX?

In the previous week, Immunic had 1 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 7 mentions for Immunic and 6 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.58 beat Immunic's score of 0.77 indicating that Bright Minds Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bright Minds Biosciences 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Immunic 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, IMUX or EVO?

Immunic has higher earnings, but lower revenue than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunic N/A N/A -$97.17M -$5.58 N/A Evotec $891.97M 0.77 -$117.12M N/A N/A

Is IMUX or EVO more profitable?

Immunic has a net margin of 0.00% compared to Evotec's net margin of -26.20%. Evotec's return on equity of -24.93% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Immunic N/A -220.75% -132.04% Evotec -26.20% -24.93% -11.35%

Does the media prefer IMUX or EVO?

In the previous week, Immunic had 4 more articles in the media than Evotec. MarketBeat recorded 7 mentions for Immunic and 3 mentions for Evotec. Immunic's average media sentiment score of 0.77 beat Evotec's score of 0.24 indicating that Immunic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunic 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evotec 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IMUX or GYRE more profitable?

Immunic has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -5.44%. Gyre Therapeutics' return on equity of 3.13% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Immunic N/A -220.75% -132.04% Gyre Therapeutics -5.44% 3.13% 2.67%

Does the media refer more to IMUX or GYRE?

In the previous week, Immunic had 4 more articles in the media than Gyre Therapeutics. MarketBeat recorded 7 mentions for Immunic and 3 mentions for Gyre Therapeutics. Immunic's average media sentiment score of 0.77 beat Gyre Therapeutics' score of 0.00 indicating that Immunic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunic 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gyre Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Immunic (IMUX) Competitors

$14.23 +0.13 (+0.93%)

As of 03:41 PM Eastern

Compare

IMUX vs. AURA, CADL, DRUG, EVO, and GYRE

Should you buy Immunic stock or one of its competitors? MarketBeat compares Immunic with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immunic include Aura Biosciences (AURA), Candel Therapeutics (CADL), Bright Minds Biosciences (DRUG), Evotec (EVO), and Gyre Therapeutics (GYRE).

How does Immunic compare to Aura Biosciences?

Immunic (NASDAQ:IMUX) and Aura Biosciences (NASDAQ:AURA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

Aura Biosciences' return on equity of -78.12% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-220.75%	-132.04%
Aura Biosciences	N/A	-78.12%	-64.08%

Aura Biosciences is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A

Immunic has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market.

Immunic currently has a consensus target price of $47.57, indicating a potential upside of 231.65%. Aura Biosciences has a consensus target price of $20.50, indicating a potential upside of 187.36%. Given Immunic's stronger consensus rating and higher possible upside, equities research analysts clearly believe Immunic is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Immunic had 7 more articles in the media than Aura Biosciences. MarketBeat recorded 7 mentions for Immunic and 0 mentions for Aura Biosciences. Immunic's average media sentiment score of 0.77 beat Aura Biosciences' score of 0.00 indicating that Immunic is being referred to more favorably in the media.

Company	Overall Sentiment
Immunic	Positive
Aura Biosciences	Neutral

51.8% of Immunic shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 5.5% of Immunic shares are owned by company insiders. Comparatively, 1.9% of Aura Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Immunic beats Aura Biosciences on 10 of the 14 factors compared between the two stocks.

How does Immunic compare to Candel Therapeutics?

Immunic (NASDAQ:IMUX) and Candel Therapeutics (NASDAQ:CADL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

51.8% of Immunic shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 5.5% of Immunic shares are owned by insiders. Comparatively, 14.3% of Candel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Candel Therapeutics' return on equity of -60.42% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-220.75%	-132.04%
Candel Therapeutics	N/A	-60.42%	-41.33%

Immunic presently has a consensus price target of $47.57, suggesting a potential upside of 231.65%. Candel Therapeutics has a consensus price target of $18.57, suggesting a potential upside of 78.21%. Given Immunic's stronger consensus rating and higher probable upside, analysts plainly believe Immunic is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Immunic had 3 more articles in the media than Candel Therapeutics. MarketBeat recorded 7 mentions for Immunic and 4 mentions for Candel Therapeutics. Immunic's average media sentiment score of 0.77 beat Candel Therapeutics' score of 0.19 indicating that Immunic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunic	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Candel Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immunic has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.51, suggesting that its stock price is 151% less volatile than the broader market.

Candel Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

Summary

Immunic beats Candel Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Immunic compare to Bright Minds Biosciences?

Bright Minds Biosciences (NASDAQ:DRUG) and Immunic (NASDAQ:IMUX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

In the previous week, Immunic had 1 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 7 mentions for Immunic and 6 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.58 beat Immunic's score of 0.77 indicating that Bright Minds Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bright Minds Biosciences	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Immunic	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bright Minds Biosciences has a beta of -5.27, suggesting that its share price is 627% less volatile than the broader market. Comparatively, Immunic has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market.

Bright Minds Biosciences currently has a consensus target price of $143.83, suggesting a potential upside of 83.37%. Immunic has a consensus target price of $47.57, suggesting a potential upside of 231.65%. Given Immunic's higher probable upside, analysts plainly believe Immunic is more favorable than Bright Minds Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00

Bright Minds Biosciences' return on equity of -20.58% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-20.58%	-20.25%
Immunic	N/A	-220.75%	-132.04%

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A

40.5% of Bright Minds Biosciences shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by company insiders. Comparatively, 5.5% of Immunic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Bright Minds Biosciences beats Immunic on 7 of the 13 factors compared between the two stocks.

How does Immunic compare to Evotec?

Immunic (NASDAQ:IMUX) and Evotec (NASDAQ:EVO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

Immunic currently has a consensus target price of $47.57, indicating a potential upside of 231.65%. Evotec has a consensus target price of $3.00, indicating a potential upside of 54.56%. Given Immunic's stronger consensus rating and higher possible upside, equities analysts clearly believe Immunic is more favorable than Evotec.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00
Evotec	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Immunic had 4 more articles in the media than Evotec. MarketBeat recorded 7 mentions for Immunic and 3 mentions for Evotec. Immunic's average media sentiment score of 0.77 beat Evotec's score of 0.24 indicating that Immunic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunic	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evotec	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immunic has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, Evotec has a beta of 1.96, indicating that its share price is 96% more volatile than the broader market.

Immunic has a net margin of 0.00% compared to Evotec's net margin of -26.20%. Evotec's return on equity of -24.93% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-220.75%	-132.04%
Evotec	-26.20%	-24.93%	-11.35%

Immunic has higher earnings, but lower revenue than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A
Evotec	$891.97M	0.77	-$117.12M	N/A	N/A

51.8% of Immunic shares are held by institutional investors. Comparatively, 5.8% of Evotec shares are held by institutional investors. 5.5% of Immunic shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Immunic beats Evotec on 10 of the 14 factors compared between the two stocks.

How does Immunic compare to Gyre Therapeutics?

Immunic (NASDAQ:IMUX) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

51.8% of Immunic shares are held by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are held by institutional investors. 5.5% of Immunic shares are held by company insiders. Comparatively, 9.5% of Gyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Immunic had 4 more articles in the media than Gyre Therapeutics. MarketBeat recorded 7 mentions for Immunic and 3 mentions for Gyre Therapeutics. Immunic's average media sentiment score of 0.77 beat Gyre Therapeutics' score of 0.00 indicating that Immunic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunic	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gyre Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immunic presently has a consensus price target of $47.57, indicating a potential upside of 231.65%. Gyre Therapeutics has a consensus price target of $17.00, indicating a potential upside of 176.42%. Given Immunic's stronger consensus rating and higher possible upside, equities analysts plainly believe Immunic is more favorable than Gyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00
Gyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Gyre Therapeutics has higher revenue and earnings than Immunic. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A
Gyre Therapeutics	$116.59M	5.88	$5.03M	-$0.09	N/A

Immunic has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market.

Immunic has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -5.44%. Gyre Therapeutics' return on equity of 3.13% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-220.75%	-132.04%
Gyre Therapeutics	-5.44%	3.13%	2.67%

Summary

Immunic beats Gyre Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Immunic News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMUX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMUX vs. The Competition

Export

Metric	Immunic	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$193.92M	$11.44B	$6.80B	$13.01B
Dividend Yield	N/A	2.74%	2.60%	10.03%
P/E Ratio	-2.55	791.58	279.98	25.51
Price / Sales	N/A	947.06	649.35	116.02
Price / Cash	N/A	14.82	28.64	34.82
Price / Book	-26.08	10.44	11.15	6.35
Net Income	-$97.17M	$2.80B	$3.48B	$347.60M
7 Day Performance	7.53%	1.86%	2.51%	3.14%
1 Month Performance	-3.08%	-2.90%	-2.78%	-2.08%
1 Year Performance	46.64%	155.40%	64.32%	21.27%

Immunic Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMUX Immunic	3.4883 of 5 stars	$14.23 +0.9%	$47.57 +234.3%	+51.4%	$193.20M	N/A	N/A	70	Upcoming Earnings
AURA Aura Biosciences	2.0875 of 5 stars	$7.16 +1.6%	$20.50 +186.3%	+4.5%	$728.88M	N/A	N/A	50
CADL Candel Therapeutics	2.7934 of 5 stars	$9.96 +4.2%	$18.57 +86.5%	+60.1%	$700.46M	N/A	N/A	60	News Coverage
DRUG Bright Minds Biosciences	2.9534 of 5 stars	$71.91 +0.8%	$143.83 +100.0%	+119.4%	$694.20M	N/A	N/A	N/A	Positive News
EVO Evotec	3.6133 of 5 stars	$1.92 -1.0%	$3.00 +56.3%	-51.7%	$690.17M	$891.97M	N/A	4,553

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMUX) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunic (IMUX) Competitors

IMUX vs. AURA, CADL, DRUG, EVO, and GYRE

How does Immunic compare to Aura Biosciences?

Summary

How does Immunic compare to Candel Therapeutics?

Summary

How does Immunic compare to Bright Minds Biosciences?

Summary

How does Immunic compare to Evotec?

Summary

How does Immunic compare to Gyre Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMUX vs. The Competition

Immunic Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunic (IMUX) Competitors

IMUX vs. AURA, CADL, DRUG, EVO, and GYRE

How does Immunic compare to Aura Biosciences?

Is IMUX or AURA more profitable?

Which has preferable valuation and earnings, IMUX or AURA?

Which has more risk & volatility, IMUX or AURA?

Do analysts rate IMUX or AURA?

Does the media favor IMUX or AURA?

Do insiders and institutionals believe in IMUX or AURA?

Summary

How does Immunic compare to Candel Therapeutics?

Do institutionals & insiders hold more shares of IMUX or CADL?

Is IMUX or CADL more profitable?

Do analysts prefer IMUX or CADL?

Does the media prefer IMUX or CADL?

Which has more volatility and risk, IMUX or CADL?

Which has better valuation and earnings, IMUX or CADL?

Summary

How does Immunic compare to Bright Minds Biosciences?

Does the media favor DRUG or IMUX?

Which has more volatility and risk, DRUG or IMUX?

Do analysts prefer DRUG or IMUX?

Is DRUG or IMUX more profitable?

Which has higher earnings & valuation, DRUG or IMUX?

Do institutionals & insiders hold more shares of DRUG or IMUX?

Summary

How does Immunic compare to Evotec?

Do analysts recommend IMUX or EVO?

Does the media prefer IMUX or EVO?

Which has more risk & volatility, IMUX or EVO?

Is IMUX or EVO more profitable?

Which has better valuation & earnings, IMUX or EVO?

Do insiders and institutionals have more ownership in IMUX or EVO?

Summary

How does Immunic compare to Gyre Therapeutics?

Do insiders & institutionals believe in IMUX or GYRE?

Does the media refer more to IMUX or GYRE?

Do analysts prefer IMUX or GYRE?

Which has preferable valuation and earnings, IMUX or GYRE?

Which has more volatility & risk, IMUX or GYRE?

Is IMUX or GYRE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMUX vs. The Competition

Immunic Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools